Aktuellt
SENASTE
In our view, Hansa Biopharma’s ability to progress the progress of the anti-GBM opportunity for the imlifidase platform is distinctly positive. This follows a successful pre-IND meeting with the FDA. Recently we have seen several FDA delays in this sector, and Hansa’s ability to timely progress this candidate to the third pivotal Phase 3 trial is an achievement.
LÄS MER
